Clinical trial
Study Evaluating LXR-623 in Healthy Subjects
NCT00366522 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Completed
Key facts
| NCT number | NCT00366522 |
|---|---|
| Title | Study Evaluating LXR-623 in Healthy Subjects |
| Official title | Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of LXR-623 Administered Orally to Healthy Subjects |
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Healthy |
| Intervention type | Drug |
| Interventions | LXR-623 |
| Start date | Aug 1, 2006 |
| Primary completion | Sep 1, 2006 |
| Completion | Sep 1, 2006 |
| First posted | Aug 21, 2006 |
| Last update posted | Aug 7, 2009 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: